Connor, Clark & Lunn Investment Management (CC&L)
RNAM

Connor, Clark & Lunn Investment Management (CC&L)’s Avidity Biosciences RNAM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-217,855
Closed -$6.34M – 1575
2024
Q4 		$6.34M Buy
217,855
+830
+0.4% +$34.7K 0.03% 422
2024
Q3 		$9.97M Buy
217,025
+211,512
+3,837% +$9.18M 0.05% 281
2024
Q2 		$225K Buy
+5,513
New +$158K ﹤0.01% 1241

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RNAM Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 217,855 shares — an estimated $6.34M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RNAM in Q2 2024 and held it in 3 quarters. The position peaked at $9.97M in Q3 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 217,855 Avidity Biosciences shares in Q1 2025, an estimated $6.34M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Avidity Biosciences in Q2 2024 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Avidity Biosciences position peaked at $9.97M in Q3 2024.
  • 220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.